Immunogen (IMGN) Misses Q1 EPS Views; Revenue Light of Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ImmunoGen Reports Financial Results for Quarter Ended September 30 and Reviews Business Highlights
October 28, 2016 6:30 AM EDTPhase 3 FORWARD I Trial of Mirvetuximab Soravtansine On Track to Begin before Year End
FORWARD II Trial Assessing Mirvetuximab Soravtansine Combinations with Avastin®, Carboplatin, Doxil®, and Keytruda® Ongoing
Strategic Review Completed to Strengthen Underlying Business and Drive Long-term Growth
Conference Call to be Held at 8:00am ET Today
WALTHAM, Mass.--(BUSINESS WIRE)--... More
